Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study

Arch Dermatol Res. 2024 Oct 9;316(9):667. doi: 10.1007/s00403-024-03419-w.

¹ 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, I. Dragoumi 5, Athens, 161 21, Greece.
² 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, I. Dragoumi 5, Athens, 161 21, Greece. [email protected].
³ Department of Dermatology and Venereology NHS, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.

^# Contributed equally.

No abstract available

Keywords: Interleukin-23; Obesity; Psoriasis; Risankizumab.

Publication types